Myovant Sciences Ltd.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Myovant Sciences Ltd.
Myovant's Orgovyx was just approved by the US FDA for prostate cancer and could be approved soon for two women's health indications.
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
The miss on improving castration resistance-free survival in Phase III trial is not likely to affect the ongoing FDA review, the company and analysts agree.
Public Company Edition: The German mRNA-focused company could raise up to $245m based on its proposed price range, but investor interest could drive the offering’s total higher. Also, Perceptive launches another SPAC, Regeneron sells $2bn in debt and Biohaven secures up to $950m.
- Antisense, Oligonucleotides
- Other Names / Subsidiaries
- Myovant Sciences GmbH
- Myovant Sciences, Inc.